Satellos Bioscience Inc. MSLE
7.19 USD +0.84 (+13.23%)
At closeNov 6, 2026, 4:00 PM EST
7.19 0.00 0.00%
After hours · Nov 6, 4:00 PM ET
6.42 Day range 7.46
5.59 52-week range 13.01
- YTD
- +22.28%
- 1 year
- +26.14%
News
benzinga.com Satellos Bioscience Switches BASECAMP Phase 2 Primary Endpoint To MRI Fat Fraction Following FDA Feedback Fat fraction, together with clinical endpoints, may support a potential accelerated approval pathway for forazapadinProtocol amendment submitted to implement the new primary efficacy endpointTopline…- benzinga.com Craig-Hallum Initiates Coverage On Satellos Bioscience with Buy Rating, Announces Price Target of $24 Craig-Hallum analyst Adam Vogel initiates coverage on Satellos Bioscience (NASDAQ:MSLE) with a Buy rating and announces Price Target of $24.
benzinga.com Satellos Granted US Patent Covering Lead Drug Candidate Forazapadin And Broader AAK1 Inhibitor Platform Satellos Bioscience Inc. (NASDAQ:MSLE, TSX:MSCL), a clinical-stage drug development company developing potentially life-improving medicines to treat degenerative muscle diseases, today announced that…
benzinga.com Satellos Bioscience Completes Enrollment For BASECAMP, Phase 2 Clinical Trial Evaluating Forazapadin For Treatment Of Duchenne Muscular Dystrophy In Ambulatory Boys 7 To 10 Years Of Age Satellos Bioscience Inc. (NASDAQ:MSLE, TSX:MSCL), a clinical-stage drug development company developing life-improving medicines to treat degenerative muscle diseases, today announced that enrollment…
benzinga.com FDA Clears Satellos Bioscience’s IND Application For Forazapadin For Treatment Of Facioscapulohumeral Muscular Dystrophy FDA clearance expands development of forazapadin into a second degenerative muscle disease with significant unmet medical needFSHD Canada Foundation to provide up to US$5 million in non-dilutive…- benzinga.com HC Wainwright & Co. Reiterates Buy on Satellos Bioscience, Maintains $18 Price Target HC Wainwright & Co. analyst Arthur He reiterates Satellos Bioscience (NASDAQ:MSLE) with a Buy and maintains $18 price target.
- benzinga.com Satellos Bioscience Q2 EPS $(0.56) Misses $(0.45) Estimate Satellos Bioscience (NASDAQ:MSLE) reported quarterly losses of $(0.56) per share which missed the analyst consensus estimate of $(0.45) by 24.44 percent. This is a 43.59 percent decrease over losses…
benzinga.com HC Wainwright & Co. Maintains Buy on Satellos Bioscience, Raises Price Target to $18 HC Wainwright & Co. analyst Arthur He maintains Satellos Bioscience (NASDAQ:MSLE) with a Buy and raises the price target from $11 to $18.
benzinga.com Satellos Bioscience Duchenne Drug Candidate's Interim Data Boosts Confidence Satellos reports six-month interim data showing SAT-3247 improved muscle composition, maintained strength, and remained well-tolerated in DMD.
benzinga.com 12 Health Care Stocks Moving In Wednesday's Pre-Market Session Gainers Catheter Precision (AMEX:VTAK) shares moved upwards by 55.8% to $1.11 during Wednesday's pre-market session. The company's market cap stands at $2.5 million. Innovative Eyewear (NASDAQ:LUCY)…
benzinga.com Satellos Bioscience Announces Six-Month Interim Data From TRAILHEAD Evaluating SAT-3247 In Adults With Duchenne Muscular Dystrophy; All Four Participants Showed Decline In Fat Fraction As Measured By MRI Fat fraction mean improvement of 3.7% from 49.7% at TRAILHEAD baseline to 46.0% at month 6, suggesting improved muscle compositionAll four participants showed an increase in TE99C, a measure of…- benzinga.com Satellos Gets FDA Fast Track Status For Duchenne Drug Satellos Bioscience Inc. (NASDAQ:MSLE, TSX:MSCL) ("Satellos" or the "Company"), a clinical-stage biotechnology company developing novel therapies to treat degenerative muscle diseases, today announced
- benzinga.com HC Wainwright & Co. Reiterates Buy on Satellos Bioscience, Maintains $11 Price Target HC Wainwright & Co. analyst Arthur He reiterates Satellos Bioscience (NASDAQ:MSLE) with a Buy and maintains $11 price target.
benzinga.com Earnings Scheduled For May 15, 2026 - benzinga.com Satellos Bioscience Q1 EPS $(0.53) Down From $(0.44) YoY Satellos Bioscience (NASDAQ:MSLE) reported quarterly losses of $(0.53) per share. This is a 20.45 percent decrease over losses of $(0.44) per share from the same period last year.
- benzinga.com Guggenheim Initiates Coverage On Satellos Bioscience with Buy Rating, Announces Price Target of $23 Guggenheim analyst Debjit Chattopadhyay initiates coverage on Satellos Bioscience (NASDAQ:MSLE) with a Buy rating and announces Price Target of $23.
benzinga.com HC Wainwright & Co. Maintains Buy on Satellos Bioscience, Raises Price Target to $11 HC Wainwright & Co. analyst Arthur He maintains Satellos Bioscience (NASDAQ:MSLE) with a Buy and raises the price target from $1.2 to $11.
benzinga.com 12 Health Care Stocks Moving In Wednesday's Pre-Market Session 
benzinga.com This Ligand Pharmaceuticals Analyst Begins Coverage On A Bullish Note; Here Are Top 4 Initiations For Wednesday Top Wall Street analysts changed outlook on top names. For all analyst rating changes, see analyst ratings page. Analysts' thoughts on LGND stock.- benzinga.com Cantor Fitzgerald Initiates Coverage On Satellos Bioscience with Overweight Rating Cantor Fitzgerald analyst Yanni Souroutzidis initiates coverage on Satellos Bioscience (NASDAQ:MSLE) with a Overweight rating.
- benzinga.com 12 Health Care Stocks Moving In Tuesday's Intraday Session